Breast MRI Spectroscopy
N/A
N/A
Female
Suspicion of, or Known Breast Cancer
Trial Information
Breast MRI Spectroscopy
Our aim is to perform MR Spectroscopy (MRS) on 150 evaluable patients at the end of their
routine breast MRI examination using a software package from General Electric Medical
Systems Milwaukee, WI). This will add time to the routine examination but will not involve
additional injections of contrast. We will analyze the spectroscopic data to determine if
benign lesions can be reliably differentiated from malignant ones.
Inclusion Criteria:
- Scheduled for diagnostic breast MRI examination or interventional procedure for a
known or suspected breast lesion
Exclusion Criteria:
- Patients who would be normally excluded from undergoing an MRI examination:
- Patients with a pacemaker, aneurysm clip or any other condition that would
warrant avoidance of a strong magnetic field
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To determine if spectroscopy of the breast can be performed and can be functional in a clinical environment.
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Sandra Brennan, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
03-037
NCT ID:
NCT00577915
Start Date:
May 2003
Completion Date:
December 2013
Related Keywords:
- Suspicion of, or Known Breast Cancer
- Breast cancer
- MRI spectroscopy
- Diagnostic radiology
- Breast Neoplasms
Name | Location |
|---|---|
| Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
